Veena N. Rao

Veena N. Rao

Auto-generated profile, based on publicly available information

Veena N. Rao

Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, Georgia Cancer Center for Excellence, Grady Health System, Atlanta, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Translational Medicine
Verified
Journal Article
Open access
ADArpita Desai
Arpita Desai
JXJingyao Xu
Jingyao Xu
KAKartik Aysola
Kartik Aysola
YQYunlong Qin
Yunlong Qin
COChika Okoli
Chika Okoli
VRVeena N Rao
Veena N Rao
Epithelial ovarian cancer: An overview

23 January 2009 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AMAnna W. Maniccia
Anna W. Maniccia
CLCatherine Lewis
Catherine Lewis
NBNurjahan Begum
Nurjahan Begum
JXJingyao Xu
Jingyao Xu
JCJianqi Cui
Jianqi Cui
VRVeena N. Rao
Veena N. Rao

22 February 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
YQYunlong Qin
Yunlong Qin
JXJingyao Xu
Jingyao Xu
KAKartik Aysola
Kartik Aysola
NBNurjahan Begum
Nurjahan Begum
VRVaishali Reddy
Vaishali Reddy
VRVeena N. Rao
Veena N. Rao

13 March 2009 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
VRV. N. Rao
V. N. Rao
JXJ. Xu
J. Xu
TWT. Watkins
T. Watkins
ARA. Reddy
A. Reddy
ERE. S.P. Reddy
E. S.P. Reddy
BRCA1 dysfunction is associated with hormone-responsive cancers. We have identified a consensus SUMO modification site in the amino-terminal region of BRCA1/1a/1b proteins and the mutation in this potential SUMO acceptor site (K 109 to R) impaired their ability to bind and repress ligand-dependent ERα transcriptional activity in breast cancer cells. Furthermore, we have found SUMO E2-conjugating enzyme Ubc9 to bind BRCA1 proteins. We have mapped BRCA1 [within amino acids (aa) 1-182] as the minimum domain that is sufficient for in vitro binding to Ubc9 as well as for regulating ERα activity. BRCA1 Mutant #1 (K109 to R) was impaired in its ability to both bind, as well as modulate Ubc9 mediated SUMO-dependent/independent E2-induced ERα transcriptional activity in breast cancer cells. Similarly, BRCA1 cancer-predisposing mutation (61Cys-Gly) abrogated the ability to both bind Ubc9 as well as inhibit ERα activity suggesting physiological significance. Addition of BRCA1 but not Mutant #1 to E2-induced ERα in the presence of SUMO-1 and Ubc9 resulted in the degradation of ERα suggesting BRCA1 to be a putative SUMO-1 and Ubc9-dependent E3 ubiquitin ligase for ERα. This is the first report demonstrating the participation of Ubc9 in BRCA1 E3 ubiquitin ligase mediated degradation of ERα. These results suggest a novel function for BRCA1 in regulating the dynamic cycles of SUMO and ubiquitin modifications required for ERα turn over and deregulation of this molecular switch due to lack of BRCA1 results in ERα-negative/positive breast cancers. This study will help in designing novel BRCA1 function-based targeted treatment for breast cancers.

23 June 2016
Verified
Journal Article
Open access
JXJ Xu
J Xu
AFA Footman
A Footman
YQY Qin
Y Qin
KAK Aysola
K Aysola
SBS Black
S Black
VRVn Rao
Vn Rao
Women who carry a germline mutation in BRCA1 gene typically develop triple negative breast cancers (TNBC) and high grade serous ovarian cancers (HGSOC). Previously, we reported that wild type BRCA1 proteins, unlike the disease-associated mutant BRCA1 proteins to bind the sole sumo E2-conjugating enzyme Ubc9. In this study, we have used clinically relevant cell lines with known BRCA1 mutations and report the in-vivo association of BRCA1 and Ubc9 in normal mammary epithelial cells but not in BRCA1 mutant HGSOC and TNBC cells by immunofluorescence analysis. BRCA1-mutant HGSOC/TNBC cells and ovarian tumor tissues showed increased expression of Ubc9 compared to BRCA1 reconstituted HGSOC, normal mammary epithelial cells and matched normal ovarian tissues. Knockdown of Ubc9 expression resulted in decreased proliferation and migration of BRCA1 mutant TNBC and HGSOC cells. This is the first study demonstrating the functional link between BRCA1 mutation, high Ubc9 expression and increased migration of HGSOC and TNBC cells. High Ubc9 expression due to BRCA1 mutation may trigger an early growth and transformation advantage to normal breast and ovarian epithelial cells resulting in aggressive cancers. Future work will focus on studying whether Ubc9 expression could show a positive correlation with BRCA1 linked HGSOC and basal like TNBC phenotype.

1 January 2012
Verified
Journal Article
Closed access
YQYunlong Qin
Yunlong Qin
JXJingyao Xu
Jingyao Xu
KAKartik Aysola
Kartik Aysola
GOGabriela Oprea
Gabriela Oprea
ARAvinash Reddy
Avinash Reddy
VRVeena N. Rao
Veena N. Rao